NCT02884726View on ClinicalTrials.gov

Phase 1 Study of Mesothelin-ADC

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

September 6, 2017

Study Completion Date

September 6, 2017

Conditions
Advanced Cancer
Interventions
DRUG

BMS-986148

Specified dose on specified days

Trial Locations (1)

1040045

Local Institution, Chuo-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02884726 - Phase 1 Study of Mesothelin-ADC | Biotech Hunter | Biotech Hunter